Get the latest news, insights, and market updates on OPY (Oppenheimer Holdings Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.
Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced that members of the management team will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference taking place virtually February 25-26, 2026. Presentation Details: Date and Time: Wednesday, February 25 at 4:00pm ETRegistration and Webcast: Click Here The Feb 18, 2026 - $OPY
How Recent Developments Are Rewriting The Story For Coherus Oncology (CHRS)
Coherus Oncology just saw its fair value estimate move from US$5.67 to US$6.75, as analysts refreshed their models around upcoming clinical readouts and recent corporate updates. At the same time, the implied revenue trend was reset from a 20.31% decline to a 13.53% decline, with a slightly higher discount rate of about 7.40% now used to reflect a modestly higher required return on the stock. Continue with this article to see how you can keep on top of these shifting assumptions and the... Feb 18, 2026 - $OPY
Oppenheimer Remains a Buy on Aurora Innovation (AUR)
Aurora Innovation, Inc. (NASDAQ:AUR) is one of the Best Penny Stocks That Will Skyrocket. Recently, on February 12, Oppenheimer reiterated a Buy rating on the stock with a $15 price target. On the same day, Cantor Fitzgerald also reiterated a Buy rating on the stock with a price target of $12. The ratings follow Aurora’s […] Feb 15, 2026 - $OPY
Assessing Turning Point Brands (TPB) Valuation After Oppenheimer’s Bullish Nicotine Pouch Outlook
Turning Point Brands (TPB) is back on investors’ radar after Oppenheimer issued a bullish update tied to anticipated fourth quarter 2025 performance and the company’s exposure to the growing nicotine pouch market. See our latest analysis for Turning Point Brands. The latest move takes the share price to US$131.77, building on a 14.24% 30 day share price return and a 30.18% 90 day share price return. The 1 year total shareholder return of 89.95% and very large 3 year total shareholder return... Feb 14, 2026 - $OPY
Walmart Inc. (WMT) Price Target Increased at Oppenheimer as Firm Eyes Solid Q4
Walmart Inc. (NASDAQ:WMT) is included among the 13 Best Roth IRA Stocks to Buy Now. On February 9, Oppenheimer analyst Rupesh Parikh increased his price recommendation on Walmart Inc. (NASDAQ:WMT) to $140 from $125 and maintained an Outperform rating ahead of the company’s quarterly results. The firm raised its Q4 EPS estimate toward the upper […] Feb 12, 2026 - $OPY
Satellos price target raised to $40 from $5 at Oppenheimer
Oppenheimer raised the firm’s price target on Satellos (MSLE) to $40 from $5 and keeps an Outperform rating on the shares. The firm is updating its model for U.S. listing, and adjusting for 1:12 reverse split and its increase in Duchenne muscular dystrophy market penetration. Oppenheimer sees Satellos as an arbitrage opportunity in DMD space, wherein SAT-3247 Phase II randomized data could move Satellos up 300%-500%/-90%. President's Day Sale - 70% OffUnlock hedge fund-level data and powerful in Feb 11, 2026 - $OPY
How The Narrative Around Modine Manufacturing (MOD) Is Shifting With New Targets And Data Center Growth
Modine Manufacturing’s latest analyst update centers on a higher fair value estimate, now about US$249 versus the prior US$183, supported by refreshed assumptions for revenue growth and discount rate. In simple terms, Street models now incorporate stronger dollar revenue expansion over time while only slightly adjusting the risk profile that feeds into the valuation framework. Stay tuned to see how you can track these shifting inputs and keep up with the evolving Modine narrative going... Feb 11, 2026 - $OPY
We use cookies and similar technologies to collect and process data such as browsing activity or unique identifiers.
Selecting "Allow All" to help us understand site usage and improve the platform.
Choosing "Essential Cookies Only" enables only the cookies necessary for core site functions, such as staying logged in.
For more information, please see our Privacy Policy.
Continue with Google
Continue with Facebook
Continue with Microsoft
Continue with Apple